Further to our intimation dated September 27, 2024 on the inspection conducted by the Unites States Food & Drug Administration (USFDA) at our Company''s manufacturing facility located at Taloja, we wish to inform you that the Company has received Establishment Inspection Report (EIR). The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded the inspection is "closed" under 21 CFR 20.64 (d) (3)